Trial Profile

A Randomized, Open-label Study of Dapagliflozin in Patients With or Without Type 2 Diabetes Admitted With Acute Heart Failure

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 18 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dapagliflozin (Primary) ; Bumetanide; Diuretics; Diuretics; Furosemide
Indications Decompensated heart failure; Type 2 diabetes mellitus
Focus Therapeutic Use
Acronyms DICTATE-AHF

Most Recent Events

21 Aug 2023 According to an AstraZeneca media release, data from this study will be presented at the European Society of Cardiology (ESC) Congress 2023.
17 May 2023 Status changed from recruiting to completed.
06 Feb 2023 Planned End Date changed from 31 Jan 2023 to 31 Dec 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com